May 31 2019 This Week in Cardiology May 31 2019 This Week in Cardiology

Tricuspid valve repair, aortic stenosis, His-bundle pacing, deprescribing loop diuretics, and ‘ leakage ’ are covered in this week ’ s on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news

Related Links:

We report two cases of patients with concomitant severe symptomatic aortic stenosis and infrarenal abdominal aortic aneurysm successfully treated with combined transfemoral transcatheter aortic valve implantation (TAVI) and endovascular aortic aneurysm repair (EVAR).
Source: Annals of Vascular Surgery - Category: Surgery Authors: Tags: Case Report Source Type: research
Authors: Muntané-Carol G, Guimaraes L, Ferreira-Neto AN, Wintzer-Wehekind J, Junquera L, Del Val D, Faroux L, Philippon F, Rodés-Cabau J Abstract Introduction: Transcatheter aortic replacement (TAVR) has revolutionized the treatment of aortic stenosis during the last years. Despite improvements in transcatheter heart valve systems, the rate of conduction disturbances after TAVR, particularly new-onset left bundle branch block (new-onset LBBB), has not decreased over time. Areas covered: Overview of the current data regarding new-onset LBBB post-TAVR focusing on clinical outcomes. Expert opinion: New-o...
Source: Expert Review of Medical Devices - Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research
Conclusions: Over a 10-year period, incidentally detected cardiac amyloidosis occurred in 0.2% of the mitral valve surgical cases. The outcomes for these patients undergoing mitral valve surgery were excellent, with no complications or deaths attributable to surgery at a mean follow-up of 1,023 days.Cardiology
Source: Cardiology - Category: Cardiology Source Type: research
Heyde described aortic stenosis and gastrointestinal bleeding in the 1950s. Since then, a link with intestinal angiodysplasia and abnormalities of von Willebrand factor (VWF) has been noted. Loss of the highest-molecular-weight multimers of VWF and bleeding also have been described in subaortic stenosis in hypertrophic cardiomyopathy, in isolated mitral and aortic insufficiency, in endocarditis, in patients with prosthetic valve stenosis or regurgitation, and in patients with left ventricular assist devices (LVADs). Bleeding tends to recur with local treatment of angiodysplasias, whereas cardiac repair or removal of LVAD e...
Source: Clinics in Geriatric Medicine - Category: Geriatrics Authors: Source Type: research
We report a case of airway compression and respiratory compromise resulting from injury to the right subclavian artery during TAVR.
Source: A&A Case Reports - Category: Anesthesiology Tags: Case Reports Source Type: research
Abstract Valvular heart diseases are one of the most frequent causes for heart failure. Degenerative diseases of the aortic and mitral valve as well as a dysfunctional tricuspid valve disease result in a worse clinical outcome if severe. Minimal-invasive, surgical and/or catheter-based structural heart disease (SHD) interventions have recently seen a dramatic increase. Transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) is a disruptive technology, and next generation devices and careful patient selection will minimize limitations of TAVI such as paravalvular leak, conductance disturbance...
Source: Journal of Cardiology - Category: Cardiology Authors: Tags: J Cardiol Source Type: research
Congenital aortic stenosis is a lifelong disease often requiring multiple interventions. Management remains controversial. Surgical repair was first described by Lillehei and colleagues in 1956 [1], and has evolved from simple commissurotomy to complex repairs utilising cusp extension techniques with pericardial patches. However, over the past three decades, balloon aortic valvuloplasty has been the intervention of choice for many centres, seen to be a safer and less invasive alternative. An important article by Auld and colleagues is published in the current issue of Heart, Lung and Circulation [2].
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Editorial Source Type: research
Condition:   Aortic Valve Stenosis Intervention:   Device: TAVR Sponsors:   IHF GmbH - Institut für Herzinfarktforschung;   Boston Scientific Group;   Yale University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR), sometimes called transcatheter aortic valve implantation, is a relatively new therapy that was first approved for use in the United States in 2011.1 Since the therapy's introduction, TAVR has increasingly become an effective alternative to surgical aortic valve repair to treat symptomatic aortic stenosis (AS) in high surgical risk or inoperable patients.2-4 Demand for this procedure has continued to grow with an increase in the number of health care centers performing TAVR procedures nationwide and continuing research extending the procedure for populations with AS.
Source: Journal of PeriAnesthesia Nursing - Category: Nursing Authors: Tags: Critical Care Connection Source Type: research
More News: Aortic Stenosis | Cardiology | Gastroschisis Repair | Heart | Heart Valve Surgery | Podcasts